Paxlovid looked like a COVID game-changer, but in vaccinated adults the real story is far more complicated
The results of two clinical trials—led by the Upstream Lab at St. Michael's Hospital in Toronto and Oxford University, published in the New England Journal of Medicine—provide new evidence to consider when funding, prescribing, or taking Paxlovid to treat COVID-19.
ORIGINAL SOURCE →via Medical Xpress
ADVERTISEMENT
⚡ STAY AHEAD
Events like this, convergence-verified across 689 sources, land in your inbox every Sunday. Free.
GET THE SUNDAY BRIEFING →RELATED · CA
- [FINANCE] Without Formal Trade Talks, Canada and the U.S. Go Public With Their Grievances
- [FINANCE] BofA cuts CME Group stock price target on higher costs outlook - Investing.com Canada
- [FINANCE] RBC Hires Industrials Bankers Gandhi, Choi in Advisory Push
- [HEALTH] Working outside the home protected mental health for older adults during the pandemic, finds study
- [DIPLOMACY] Canada offers mines and more in $730b investment bid slammed as unsustainable
- [FINANCE] GIC savers catch a second wind as Hormuz blockade keeps Canadian interest rate hike bets alive - The Globe and Mail